Advanced Ovarian Cancer: Current Treatment Landscape in Second- and Later-Line Settings
May 30th 2023Expert oncologists review the current PARP inhibitor treatment indications for patients with advanced ovarian cancer and discuss how to best manage patients who have been impacted by the recent updates to the PARP inhibitors.
Read More
Dr Coleman on Response Rates With Mirvetuximab Soravtansine in Ovarian Cancer
March 27th 2023Robert L. Coleman, MD, FACOG, FACS, discusses an analysis of the phase 3 SORAYA trial evaluating response rates in patients with platinum-resistant ovarian cancer who received mirvetuximab soravtansine at different points in their disease course.
Read More
Dr. Coleman on the Clinical Implications of the innovaTV 204 Trial in Cervical Cancer
September 21st 2020Robert L. Coleman, MD, FACOG, FACS, discusses the clinical implications of the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 trial in women with previously treated recurrent or metastatic cervical cancer.
Read More
Dr. Coleman on the Use of Veliparib in Ovarian Cancer
January 29th 2020Robert L. Coleman, MD, FACOG, FACS, professor and Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the use of veliparib in ovarian cancer.
Read More